Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.46
RHHBY's Cash to Debt is ranked higher than
53% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. RHHBY: 0.46 )
RHHBY' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 0.46

Equity to Asset 0.29
RHHBY's Equity to Asset is ranked higher than
56% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RHHBY: 0.29 )
RHHBY' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.59
Current: 0.29

0.13
0.59
F-Score: 5
Z-Score: 3.81
M-Score: -2.79
WACC vs ROIC
8.24%
35.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.26
RHHBY's Operating margin (%) is ranked higher than
95% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. RHHBY: 28.26 )
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.53   Max: 33.69
Current: 28.26

4.53
33.69
Net-margin (%) 18.71
RHHBY's Net-margin (%) is ranked higher than
93% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. RHHBY: 18.71 )
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.67   Max: 30.16
Current: 18.71

-13.67
30.16
ROE (%) 44.95
RHHBY's ROE (%) is ranked higher than
98% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. RHHBY: 44.95 )
RHHBY' s 10-Year ROE (%) Range
Min: -16.17   Max: 82.24
Current: 44.95

-16.17
82.24
ROA (%) 14.01
RHHBY's ROA (%) is ranked higher than
96% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. RHHBY: 14.01 )
RHHBY' s 10-Year ROA (%) Range
Min: -5.78   Max: 17.58
Current: 14.01

-5.78
17.58
ROC (Joel Greenblatt) (%) 71.03
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. RHHBY: 71.03 )
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.9   Max: 84.52
Current: 71.03

6.9
84.52
Revenue Growth (3Y)(%) 5.00
RHHBY's Revenue Growth (3Y)(%) is ranked higher than
81% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. RHHBY: 5.00 )
RHHBY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.3   Max: 391.7
Current: 5

-2.3
391.7
EBITDA Growth (3Y)(%) 3.10
RHHBY's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -7.20 vs. RHHBY: 3.10 )
RHHBY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -5.1   Max: 280
Current: 3.1

-5.1
280
EPS Growth (3Y)(%) -0.50
RHHBY's EPS Growth (3Y)(%) is ranked higher than
81% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. RHHBY: -0.50 )
RHHBY' s 10-Year EPS Growth (3Y)(%) Range
Min: -3.8   Max: 341.1
Current: -0.5

-3.8
341.1
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RHHBY Guru Trades in Q1 2014

Ken Fisher 1,803,070 sh (+99%)
Bill Frels 2,138,396 sh (+5.45%)
» More
Q2 2014

RHHBY Guru Trades in Q2 2014

Bill Frels 2,184,810 sh (+2.17%)
Ken Fisher 1,813,443 sh (-49.71%)
» More
Q3 2014

RHHBY Guru Trades in Q3 2014

Bill Frels 2,391,096 sh (+9.44%)
Ken Fisher 1,891,406 sh (+4.3%)
» More
Q4 2014

RHHBY Guru Trades in Q4 2014

Ken Fisher 2,823,025 sh (+49.26%)
Bill Frels 2,609,371 sh (+9.13%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.80
RHHBY's P/E(ttm) is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 24.80 )
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.05   Max: 36.39
Current: 24.8

13.05
36.39
Forward P/E 2.27
RHHBY's Forward P/E is ranked higher than
94% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 2.27 )
N/A
PE(NRI) 25.20
RHHBY's PE(NRI) is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 25.20 )
RHHBY' s 10-Year PE(NRI) Range
Min: 13.05   Max: 44.62
Current: 25.2

13.05
44.62
P/B 10.60
RHHBY's P/B is ranked higher than
54% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. RHHBY: 10.60 )
RHHBY' s 10-Year P/B Range
Min: 2.64   Max: 17.39
Current: 10.6

2.64
17.39
P/S 4.56
RHHBY's P/S is ranked higher than
86% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. RHHBY: 4.56 )
RHHBY' s 10-Year P/S Range
Min: 2.38   Max: 6.45
Current: 4.56

2.38
6.45
PFCF 18.20
RHHBY's PFCF is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 18.20 )
RHHBY' s 10-Year PFCF Range
Min: 8.6   Max: 39.65
Current: 18.2

8.6
39.65
POCF 14.76
RHHBY's POCF is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 14.76 )
RHHBY' s 10-Year POCF Range
Min: 6.98   Max: 25.96
Current: 14.76

6.98
25.96
EV-to-EBIT 17.57
RHHBY's EV-to-EBIT is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 17.57 )
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 32
Current: 17.57

7.9
32
PEG 6.63
RHHBY's PEG is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 6.63 )
RHHBY' s 10-Year PEG Range
Min: 0.3   Max: 7.66
Current: 6.63

0.3
7.66
Shiller P/E 24.00
RHHBY's Shiller P/E is ranked higher than
98% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 24.00 )
RHHBY' s 10-Year Shiller P/E Range
Min: 13.45   Max: 110.34
Current: 24

13.45
110.34
Current Ratio 1.35
RHHBY's Current Ratio is ranked higher than
56% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. RHHBY: 1.35 )
RHHBY' s 10-Year Current Ratio Range
Min: 1.35   Max: 3.75
Current: 1.35

1.35
3.75
Quick Ratio 1.01
RHHBY's Quick Ratio is ranked higher than
55% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. RHHBY: 1.01 )
RHHBY' s 10-Year Quick Ratio Range
Min: 1.01   Max: 3.22
Current: 1.01

1.01
3.22
Days Inventory 182.80
RHHBY's Days Inventory is ranked higher than
83% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 182.80 )
RHHBY' s 10-Year Days Inventory Range
Min: 109.1   Max: 245.45
Current: 182.8

109.1
245.45
Days Sales Outstanding 65.90
RHHBY's Days Sales Outstanding is ranked higher than
81% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 112.01 vs. RHHBY: 65.90 )
RHHBY' s 10-Year Days Sales Outstanding Range
Min: 65.9   Max: 86.72
Current: 65.9

65.9
86.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.16
RHHBY's Dividend Yield is ranked higher than
89% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. RHHBY: 3.16 )
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74   Max: 4.55
Current: 3.16

0.74
4.55
Dividend Payout 0.73
RHHBY's Dividend Payout is ranked higher than
95% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 0.73 )
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.59
Current: 0.73

0.21
0.59
Dividend growth (3y) 5.70
RHHBY's Dividend growth (3y) is ranked higher than
79% of the 96 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. RHHBY: 5.70 )
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: 5.7

0
27.3
Yield on cost (5-Year) 2.85
RHHBY's Yield on cost (5-Year) is ranked higher than
83% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. RHHBY: 2.85 )
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 0.68   Max: 4.18
Current: 2.85

0.68
4.18
Share Buyback Rate -0.50
RHHBY's Share Buyback Rate is ranked higher than
93% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: -9.80 vs. RHHBY: -0.50 )
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.70
RHHBY's Price/DCF (Projected) is ranked higher than
98% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 1.70 )
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.25   Max: 7.13
Current: 1.7

1.25
7.13
Price/Median PS Value 1.20
RHHBY's Price/Median PS Value is ranked higher than
82% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. RHHBY: 1.20 )
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.66   Max: 1.3
Current: 1.2

0.66
1.3
Earnings Yield (Greenblatt) 5.80
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. RHHBY: 5.80 )
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 12.7
Current: 5.8

3.1
12.7
Forward Rate of Return (Yacktman) 8.64
RHHBY's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 15.63 vs. RHHBY: 8.64 )
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 79.2
Current: 8.64

2.2
79.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.UK, 0QOK.UK, ROG N.Mexico,
Roche Holding AG Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. It has more than 60 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Diagnostics division includes five business areas: Applied Science, Molecular Diagnostics, Professional Diagnostics, Tissue Diagnosis and Diabetes Care.
» More Articles for OTCPK:RHHBY

Headlines

Articles On GuruFocus.com
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
Small Cap Biotech Growth Stocks For 2015 Mar 05 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
Roche In Expansion Mode Jan 19 2015 
Why Organovo is A Safe Buy? Dec 18 2014 
Is Organovo A Safe Buy? Dec 08 2014 
The Top 5 European Stocks Held During Q3 Nov 25 2014 
Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 22 2014 
Widely Held Guru Stocks Trading In Europe Sep 22 2014 

More From Other Websites
12:15 pm Roche Hldg's Genentech announces plans to invest more than $125 mln for the expansion of... Mar 26 2015
Can Pharma Conquer The Consumer The Way Apple Did? This App Might Help Mar 25 2015
This Biotech Is A Prime Buyout Candidate Mar 23 2015
Biogen Idec 'Results Particularly Exciting,' Bernstein Says; Lilly, Roche Get a Boost Mar 20 2015
Prothena Soars On Parkinson's Drug; Biogen In Focus Mar 19 2015
Juno Therapeutics' (JUNO) Q4 Loss Wider than Expected - Analyst Blog Mar 19 2015
Sigma-Aldrich Announces Exclusive Distribution Agreement with Roche Mar 19 2015
Celldex, Roche Ink Deal to Develop Kidney Cancer Drug - Analyst Blog Mar 18 2015
What's in Store for Juno Therapeutics this Earnings Season? - Analyst Blog Mar 16 2015
Will Inovio (INO) Disappoint This Earnings Season Again? - Analyst Blog Mar 13 2015
Xenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update Mar 12 2015
Xenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update Mar 12 2015
The Silver Lining In Big Pharma Layoffs And Site Closures? A Redistribution Of Talent And Resources Mar 12 2015
In Big Shift, 23andMe Will Invent Drugs Using Customer Data Mar 12 2015
Puma Biotechnology Up on Neratinib Study Initiation - Analyst Blog Mar 11 2015
New Report From The NEJM On Clinical Trial Reporting Further Tarnishes Biopharma's Image Mar 11 2015
AVEO Up on Pipeline News, Q4 Loss Narrower than Expected - Analyst Blog Mar 09 2015
This Top Cancer-Fighter Is Now A Bargain Mar 09 2015
Florida eye doctor at center of Menendez probe Mar 06 2015
Bristol-Myers Hits 14-Year High On Big Cancer News Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK